Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial).

PURPOSE AND METHODS: To describe the evolution of resistance to zidovudine (ZDV), lamivudine (3TC), abacavir (ABC) and nelfinavir (NFV), 113 previously untreated children in the PENTA 5 trial had resistance assayed at baseline, rebound and/or 24, 48, 72 weeks (VIRCO: phenotyping and genotyping with...

Полное описание

Библиографические подробности
Главные авторы: Gibb, D, Walker, A, Kaye, S, De Rossi, A, Ait-Khaled, M, Pillay, D, Muñoz-Fernandez, M, Loveday, C, Compagnucci, A, Dunn, D, Babiker, A
Формат: Journal article
Язык:English
Опубликовано: 2002

Схожие документы